In preclinical mouse models, AS-99 also exhibited considerable effects in suppressing bone metastases and reversing the pro-tumoral TAM-enriched metastatic bone niche, providing proof-of-concept evidence for targeting ASH1L in metastatic PCa and other malignancies. The gene discussed is ASH1L; the disease is posterior cortical atrophy.